SCHEMBL24179486

SCHEMBL24179486

ICCOc1cccc2c1cnn2C1CCCCO1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 5/20 0.39
▸ CYP4A11 Q02928 5/20 0.39
▸ RXRA P19793 1/20 0.39
▸ RXRB P28702 1/20 0.39
▸ RXRG P48443 1/20 0.39
▸ MAPK8 P45983 5/20 0.37
▸ MAPK9 P45984 5/20 0.37
▸ MAPK10 P53779 4/20 0.37
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ BCHE P06276 2/20 0.34
▸ HTR6 P50406 2/20 0.34
▸ ATR Q13535 2/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ DDB1 Q16531 1/20 0.33
▸ CRBN Q96SW2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25917394 0.89 RXRA (0.39) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30723809 0.85 RXRA (0.46) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL7272765 0.84 RXRA (0.39) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL1141392 0.83 ATR (0.47) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30724136 0.81 ALOX5AP (0.39) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL25917464 0.80 RXRA (0.40) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL25917465 0.79 RXRA (0.37) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL31628652 0.78 RXRA (0.42) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL1193030 0.78 RXRA (0.42) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL25917467 0.78 RXRA (0.36) CYP4F2CYP4A11RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242507-A1 INDAZOLE-FUSED CYCLIC COMPOUND Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) 2023-08-03 — — US disclosed
US-20230242507-A1 INDAZOLE-FUSED CYCLIC COMPOUND Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) 2023-08-03 — — US disclosed
EP-4174059-A1 INDAZOLE-FUSED CYCLIC COMPOUND Medshine Discovery Inc. (CN) 2023-05-03 — — EP disclosed
WO-2022001971-A1 INDAZOLE-FUSED CYCLIC COMPOUND 南京明德新药研发有限公司 2022-01-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242507-A1 INDAZOLE-FUSED CYCLIC COMPOUND SLC5A11, CYP11B2, CYP4F11 CYP4F2 33/4885CYP4A11 4/4885RXRA 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback